- Current report filing (8-K)
June 21 2012 - 4:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|
|
Date of Report (Date of Earliest Event Reported):
|
|
June 20, 2012
|
ADVENTRX Pharmaceuticals, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
001-32157
|
84-1318182
|
_____________________
(State or other jurisdiction
|
_____________
(Commission
|
______________
(I.R.S. Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
|
|
|
12390 El Camino Real, Suite 150, San Diego, California
|
|
92130
|
_________________________________
(Address of principal executive offices)
|
|
___________
(Zip Code)
|
|
|
|
Registrants telephone number, including area code:
|
|
858-552-0866
|
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 20, 2012, ADVENTRX Pharmaceuticals, Inc. (the Company) held its 2012 Annual Meeting of
Stockholders (the Annual Meeting). The following is a brief description of each matter voted
upon at the Annual Meeting and the number of votes cast for and against, as well as the number of
abstentions and broker non-votes as to each such matter, as applicable.
1.
|
|
To elect four directors to hold office until the next annual meeting of stockholders and
until their successors are elected and qualified or until their earlier resignation or
removal:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Broker
|
|
|
For
|
|
Against
|
|
Abstain
|
|
Non-Vote
|
Nominee
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Brian M. Culley
|
|
|
11,904,371
|
|
|
|
647,235
|
|
|
|
219,473
|
|
|
|
22,437,754
|
|
Jack Lief
|
|
|
11,534,421
|
|
|
|
1,009,830
|
|
|
|
226,828
|
|
|
|
22,437,754
|
|
David A. Ramsay
|
|
|
11,542,279
|
|
|
|
1,005,922
|
|
|
|
222,878
|
|
|
|
22,437,754
|
|
Lewis J. Shuster
|
|
|
11,538,031
|
|
|
|
1,006,180
|
|
|
|
226,868
|
|
|
|
22,437,754
|
|
In accordance with the above results, each nominee was elected to serve as director.
2.
|
|
To ratify the appointment of PricewaterhouseCoopers LLP as the Companys independent
registered public accounting firm for the fiscal year ending December 31, 2012:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
|
Broker
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-Vote
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
34,696,766
|
|
|
|
474,146
|
|
|
|
37,921
|
|
|
|
0
|
|
In accordance with the above results, the appointment of PricewaterhouseCoopers LLP was ratified.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
ADVENTRX Pharmaceuticals, Inc.
|
|
|
|
|
|
June 21, 2012
|
|
By:
|
|
/s/ Patrick L. Keran
|
|
|
|
|
|
|
|
|
|
Name: Patrick L. Keran
|
|
|
|
|
Title: President and Chief Operating Officer
|
Adventrx (AMEX:ANX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Dec 2023 to Dec 2024